To reinforce the results we obtained, Ezeife et al. (2018) reported that the ICER of osimertinib for previously untreated EGFR-mutant advanced NSCLC in Canada was $223,133/QALY gained, which was above the WTP threshold ($100,000 per QALY), suggesting osimertinib was also not cost-effective at Canadian market price. Here, EGFR is linked to non-small cell lung carcinoma.